Solara Active Pharma Sciences Limited has formally completed the closure of its wholly owned subsidiary in Brazil, with the entity now officially deregistered with the Federal Revenue of Brazil, marking the end of its corporate presence in the South American market through this non-operating entity.

Official Deregistration Confirmation

Following the company's earlier intimation dated February 21, 2025, Solara Active Pharma Sciences LTDA, Brazil has been voluntarily deregistered with the Federal Revenue of Brazil, with the deregistration taking effect from July 30, 2025. The company has now provided formal confirmation of this closure through its latest regulatory disclosure.

Financial Impact Assessment

The Brazilian subsidiary had no financial contribution to the parent company's consolidated performance. According to the regulatory disclosure, the entity recorded zero business activity and maintained nil net worth.

Regulatory Compliance Framework

The closure has been disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in accordance with SEBI Master circular dated January 30, 2026. The company has confirmed that this was a straightforward voluntary closure rather than a sale or disposal transaction.

Corporate Housekeeping Measure

The closure represents a corporate streamlining initiative, allowing Solara Active Pharma Sciences to eliminate dormant entities from its subsidiary structure. Company Secretary and Compliance Officer Pooja Jaya Kumar has confirmed that all relevant information regarding this closure is available on the company's website at solaraco.in for stakeholder reference.

The formal completion of this closure process demonstrates the company's commitment to maintaining an efficient corporate structure by removing non-operational entities that serve no business purpose.

Solara Active Pharma Sciences announced its Q3FY26 financial results, reporting revenue of ₹349 crores alongside a consolidated net loss of ₹17.43 crores. The pharmaceutical company's Board of Directors approved the unaudited financial results for the quarter ended December 31, 2025, during their meeting held on February 6, 2026. The company has engaged strategic advisors to evaluate options for its Ibuprofen business and reassess the previously announced CRAMS & Polymers business demerger.

Financial Performance Overview

The company's Q3FY26 results demonstrate revenue growth compared to the corresponding quarter of the previous year, with total income reaching ₹349 crores against ₹301.80 crores in Q3FY25. However, the company recorded a consolidated net loss of ₹17.43 crores, marking a significant shift from the ₹8.09 crores profit achieved in the same quarter last year.

Strategic Business Transformation and Management Insights

During the earnings conference call held on February 6, 2026, management provided detailed insights into the company's strategic direction. Founder and Non-Executive Director Arun Kumar acknowledged the significant challenges facing the ibuprofen business, noting that Solara was historically the largest ibuprofen manufacturer globally. The company's Growth API business segment delivered strong performance with gross margins exceeding 55% and EBITDA margins of approximately 25%. In contrast, the Base Ibuprofen API business faced persistent headwinds with negative EBITDA margins of -22.90%.

Board Decisions and Strategic Review

The Board of Directors has appointed strategic advisors to evaluate options for the Ibuprofen business, recognizing the structural challenges and pricing pressures in the commodity segment. Management emphasized that the ibuprofen derivatives business remains profitable and is part of the growth segment. The board will also reassess the previously announced scheme for the CRAMS & Polymers business split, with management indicating that an integrated structure may provide more value. A comprehensive roadmap for both initiatives is expected to be presented in the subsequent quarter.

Operational Challenges and Future Plans

The company operates facilities in Pondicherry and Vizag with combined ibuprofen capacity of 10,000-12,000 tons, but current utilization is only around 3,000 tons. The Vizag facility has been mothballed, and management plans to convert it into a multipurpose plant including high potent API capabilities within the next 5-6 months. This transformation will require increased R&D investments and new talent acquisition to support the expanded product portfolio.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Solara Active Pharma Sciences reported total income of ₹983.16 crores compared to ₹1,013.12 crores in the corresponding period last year. The company recorded a consolidated net loss of ₹17.01 crores for the nine-month period, contrasting with a profit of ₹2.64 crores in the previous year.

Financial Position and Debt Management

The company continues its rights issue program, having raised ₹311.85 crores out of the total ₹449.95 crores rights issue as of December 31, 2025. Gross debt decreased to ₹630.00 crores from ₹776.00 crores, representing a 19% reduction. CFO Sarat Kumar indicated that ₹113 crores of debt reduction came from rights issue proceeds, while ₹33 crores was generated from operational cash flows. The expected gross debt by May 2026 is projected at approximately ₹499.90 crores.